Novus Cannabis MedPlan (NDEV) Reports Q3 2025

About this update from Novus Acquisition & Development Corp.

Novus Cannabis MedPlan (NDEV) Reports Q3 2025 Novus Cannabis MedPlan (NDEV) Reports Q3 2025 Results: 18.1% EBITDA Growth and 8.85% Revenue Increase MIAMI, FL - December 17, 2025 (NEWMEDIAWIRE) - Novus Acquisition and Development Corp. (NDEV), operating as Novus Cannabis MedPlan, is a leading health plan carrier traded on the OTC Markets. The company specializes in proprietary prescription drug programs and traditional medical plans that include cannabis benefits. As an ancillary, "non-plant-touching" business (meaning it does not grow, process, or sell cannabis directly), NDEV reported business momentum during the first nine months of 2025. This strong financial performance is a direct result of the company strategically allocating its resources to self-fund key market initiatives and expand its Provider and Health Plan Network. Financial and Operational Highlights Nine Months Ended September 30, 2025 Novus demonstrated strong operational leverage during the reporting period, characterized by double-digit percentage improvements in EBITDA margins and a continued commitment to a non-dilutive capital strategy. Metric 9M 2025 9M 2024 Change (%) Gross Revenue $300,044 $273,462 +8.85% EBITDA $152,572* $124,860 +18.10% Cash & Equivalents $235,782 $219,946 +7.20% *Reflects Net Revenue correlation to EBITDA for the period. Key Financial Takeaways: Accelerated Profitability: EBITDA growth of 18.1% significantly outpaced revenue growth of 8.85%, indicating successful cost-containment measures and improved operational efficiency across the Provider and Health Plan Network. Organic Revenue Momentum: The 8.85% increase in top-line Gross Revenue reflects sustained demand for the company's proprietary prescription drug programs and integrated cannabis benefits. Strengthened Balance Sheet: Cash and Cash Equivalents rose to $235,782, a 7.2% year-over-year increase. This growth was achieved through organic cash flow, reinforcing Novus's ability to self-fund market initiatives without dilutive external financing. Margin Expansion: Net Revenue of $152,572 underscores the company's transition toward higher-margin service offerings within the ancillary healthcare space. Capital Structure Integrity and Shareholder Protection Novus remains steadfast in its commitment to a simplified capital structure and maximizing per-share value: Non-Dilutive Growth: The number of issued a...

View stock analysis, news, and events for Novus Acquisition & Development Corp.